Evidence map›Paper›PMID 40655138›Full record

ArticleFrontiers in immunology2025

Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells.

Aida López Ruiz, Eric Slaughter, Kartik Bomb, Samantha L Swedzinski, Paige J LeValley, Zaining Yun, Jacob McCoskey, Kara Levine, Jonathan Steen, Joseph Almasian and 8 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Aida López RuizDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, United States.
Eric SlaughterDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, United States.
Kartik BombDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, United States.
Samantha L SwedzinskiDepartment of Materials Science and Engineering, University of Delaware, Newark, DE, United States.
Paige J LeValleyDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, United States.
Zaining YunDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, United States.
Jacob McCoskeyEMD Millipore Corporation, Bedford, MA, United States.
Kara LevineEMD Millipore Corporation, Bedford, MA, United States.
Jonathan SteenEMD Millipore Corporation, Bedford, MA, United States.
Joseph AlmasianEMD Millipore Corporation, Bedford, MA, United States.
Aparajita ChatterjeeEMD Millipore Corporation, Bedford, MA, United States.
Christina CarbrelloEMD Millipore Corporation, Bedford, MA, United States.
Dustin S ChangAgilent Technologies, Santa Clara, CA, United States.
Hubaida FuseiniAgilent Technologies, Santa Clara, CA, United States.
Yama A AbassiAgilent Technologies, Santa Clara, CA, United States.
Abraham M LenhoffDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, United States.
Catherine A FromenDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, United States.
April M KloxinDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, United States.

Funding

Predictive Modeling & Optimal Control Framework for Model-Based Epidemic Response in DelawareP20GM103446 · NIGMS · UNIVERSITY OF DELAWARE · PI Shawn W Polson · 2012 to 2026
$67.2M
NIGMS NIH HHS P20 GM103446
6 · The paper itself

Abstract

Introduction: Cell therapies have revolutionized cancer treatment, with chimeric antigen receptor (CAR) T-cell therapies at the forefront for the treatment of hematological cancers. However, current manufacturing protocols rely on rapid T-cell activation, which can induce exhaustion and undesirable phenotypes, ultimately reducing the efficacy and persistence of CAR T-cells. Given the importance of T-cell activation as a fundamental step to achieve proliferative phenotypes for cell engineering and expansion, approaches are needed to control activation and increase CAR T-cell quality. To address this need, in this work, we utilized a bioinspired, scalable, tunable platform to direct T-cell activation and decrease exhaustion during CAR T production. Methods: Hydrogel-coated membranes (HCMs) were designed with different co-stimulatory ligands and a physiologically-relevant substrate modulus inspired by the native microenvironment in which T cells are programmed. Phenotype, activation, and exhaustion markers were used to compare T cells cultured with HCMs or industry standard TransAct. Next, transduction with a CD19 CAR lentivirus was performed, and the killing potential of the resulting CAR T product was evaluated using an Results: With this controlled and well-defined system, we hypothesized that a combination of ligands inspired by antigen-presenting cells would promote desired T-cell phenotypes with reduced exhaustion and thereby improved killing efficacy. We found memory phenotypes, minimal exhaustion, and similar activation profiles with HCMs. Additionally, increased T-cell transduction and decreased exhaustion for the CAR T population were observed with HCMs. Further, the killing potential of the resulting CAR T product was evaluated, finding improved Discussion: These results demonstrate the importance of lower T-cell exhaustion in CAR T manufacturing and present significant opportunities to modulate T-cell phenotypes for cell therapy applications using engineered bioinspired materials that display combinations of co-stimulatory molecules.

Indexed as

HydrogelsImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAntigens, CD19HumansLymphocyte ActivationT-Cell ExhaustionAntigens, CD19HydrogelsReceptors, Chimeric AntigenbioinspiredbiomaterialsCAR Tcell therapycoatinghydrogelligandT cell

Identifiers

PMID40655138
PMCPMC12245814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.